Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
U.S. Drowning Deaths Rising Again After Years of Decline
TUESDAY, May 14, 2024 (HeathDay News) -- Following decades of declines, drowning deaths are once again climbing in the United States, new government data...
About 8,000 Women Per Month Are Getting Abortion Pills Despite Their States' Bans
TUESDAY, May 14, 2024 -- While some states have moved to severely curb women's access to abortion, including abortion pills, over 8,000 women living in those...
Child Maltreatment Linked to Externalizing, Internalizing Behavior
TUESDAY, May 14, 2024 -- Child maltreatment is associated with increases in externalizing and internalizing behaviors, according to a study published online...
Large Language Models May Aid Emergency Department Triage
TUESDAY, May 14, 2024 -- Large language models (LLMs) could enhance emergency department triage workflows, according to a study published online May 7 in JAMA...
Neighborhood Inequity Tied to More People Living With Vision Difficulty, Blindness
TUESDAY, May 14, 2024 -- Residential measures of inequity are associated with a greater number of individuals living with vision difficulty and blindness...
Risk From Regular Cannabis Use Perceived as Low in Women With Disabilities
TUESDAY, May 14, 2024 -- Women with disabilities have a low likelihood of perceiving a risk for harm from weekly cannabis use, according to a study recently...
Elite Running Tied to Longer Life Expectancy
TUESDAY, May 14, 2024 -- Sub-four-minute mile runners have greater longevity than the general population, with results dating back as far as the 1950s...
Summer of 2023 Was Hottest in 2,000 Years
TUESDAY, May 14, 2024 -- High temperatures across the Northern Hemisphere last summer were scorching and frequent enough to make it the hottest summer in two...
San Francisco Set to Ban 'Forever Chemicals' in Firefighter Gear
TUESDAY, May 14, 2024 -- San Francisco is on the verge of passing a ban on "forever chemicals" in the protective clothing firefighters wear while battling...
More Studies Support Wegovy's Long-Term Weight-Loss Benefits
TUESDAY, May 14, 2024 -- Semaglutide -- the active ingredient in the blockbuster weight-loss drugs Ozempic and Wegovy -- can produce long-term weight and heart...
FDA Approves Updated Altuviiio Label With Expanded Pediatric Data Confirming Highly Effective Bleed Protection in Children With Hemophilia
Paris, May 10, 2024 -- The US Food and Drug Administration (FDA) has updated the label for Altuviiio® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN...
FDA Approves Myhibbin (mycophenolate mofetil) Oral Suspension for Prophylaxis of Organ Rejection
WOBURN, Mass. May 6, 2024 – Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to...
US FDA Approves High-Concentration, Citrate-Free Formulation of Cyltezo (adalimumab-adbm) injection
RIDGEFIELD, Conn., May 1, 2024 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the...
Neurocrine Biosciences Announces U.S. FDA Approval of Ingrezza Sprinkle (valbenazine) Capsules
SAN DIEGO, April 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved...
FDA Approves Libervant (diazepam) Buccal Film for the Treatment of Seizure Clusters in Pediatric Patients Ages 2-5 Years
WARREN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a...
Abeona Therapeutics Provides Regulatory Update on Pz-cel
CLEVELAND, April 22, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced a regulatory update for prademagene zamikeracel (pz-cel)...
Supernus Provides Regulatory Update for SPN-830
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Stealth Biotherapeutics Announces FDA Acceptance of New Drug Application for Elamipretide for the Treatment of Barth Syndrome
NEEDHAM, Mass., April 8, 2024 /PRNewswire/ — Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and...
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
DUBLIN, April 2, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has completed the rolling submission of a...
Datopotamab Deruxtecan Biologics License Application Accepted in the US for Patients with Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer
2 April 2024 -- AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US...
Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer
SHANGHAI, May 13, 2024, Mabwell, an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study of its...
Geisinger enrolls first patient in amyloid cardiomyopathy trial
DANVILLE, Pa., May 10, 2024. Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the U.S. into a cardiac...
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
RAHWAY, N.J.--(BUSINESS WIRE) May 13, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of...
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology...
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
Drugs.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.